PRDX6 contributes to selenocysteine metabolism and ferroptosis resistance
Zhiyi Chen,Alex Inague,Kamini Kaushal,Gholamreza Fazeli,Thamara N Xavier da Silva,Ancely Ferreira dos Santos,Tasneem Cheytan,Florencio Porto Freitas,Umut Yildiz,Lucas Gasparello Viviani,Rodrigo Santiago Lima,Mikaela Peglow Pinz,Isadora Medeiros,Thiago Geronimo Pires Alegria,Railmara Pereira da Silva,Larissa Regina Diniz,Simon Weinzweig,Judith Klein-Seetharaman,Andreas Trumpp,Adriana Manas,Robert Hondal,Matthias Fischer,Christoph Bartenhagen,Briana K. Shimada,Lucia A. Seale,Marietta Fabiano,Ulrich Schweizer,Luis E. Netto,Flavia Carla Meotti,Hamed Alborzinia,Sayuri Miyamoto,Jose Pedro Friedmann Angeli
DOI: https://doi.org/10.1101/2024.06.04.597364
2024-06-06
Abstract:Selenocysteine (Sec) metabolism is crucial for cellular function and ferroptosis prevention and has traditionally been thought to begin with the uptake of the Sec carrier selenoprotein P (SELENOP). Following uptake, Sec released from SELENOP undergoes metabolisation via selenocysteine lyase (SCLY), producing selenide, a substrate used by selenophosphate synthetase 2 (SEPHS2), which provides the essential selenium donor - selenophosphate - for the biosynthesis of the selenocysteine tRNA. Here, we report the discovery of an alternative pathway mediating Sec metabolisation that is independent of SCLY and mediated by peroxiredoxin 6 (PRDX6). Mechanistically, we demonstrate that PRDX6 can readily react with selenide and interact with SEPHS2, potentially acting as a selenium delivery system. Moreover, we demonstrate the presence and functional significance of this alternative route in cancer cells where we reveal a notable association between elevated expression of PRDX6 with a highly aggressive neuroblastoma subtype. Altogether, our study sheds light on a previously unrecognized aspect of Sec metabolism and its implications in ferroptosis, offering new avenues for therapeutic exploitation.
Cell Biology